FDA Removes Clinical Hold on Nomlabofusp Study for Friedreich’s Ataxia
source: pixabay.com

FDA Removes Clinical Hold on Nomlabofusp Study for Friedreich’s Ataxia

Three years after the U.S. Food and Drug Administration (FDA) first placed a full clinical hold on Larimar Therapeutics’ Phase 2 clinical study, the hold has officially been lifted. The…

Continue Reading FDA Removes Clinical Hold on Nomlabofusp Study for Friedreich’s Ataxia
ClimbFARACure: How Summiting Aconcagua Raised Friedreich’s Ataxia Awareness
source: pixabay.com

ClimbFARACure: How Summiting Aconcagua Raised Friedreich’s Ataxia Awareness

It was never just about reaching the summit of Aconcagua, the highest mountain in both the Western and Southern hemispheres. For Scott Osleeb, scaling the heights of this remarkable peak…

Continue Reading ClimbFARACure: How Summiting Aconcagua Raised Friedreich’s Ataxia Awareness
Rare Community Profiles: From Afraid to Advocate: How Natalie Found Her Power After a Friedreich’s Ataxia Diagnosis
Fotocitizen / Pixabay

Rare Community Profiles: From Afraid to Advocate: How Natalie Found Her Power After a Friedreich’s Ataxia Diagnosis

Rare Community Profiles     Rare Community Profiles is a new Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their…

Continue Reading Rare Community Profiles: From Afraid to Advocate: How Natalie Found Her Power After a Friedreich’s Ataxia Diagnosis
Now Approved: Skyclarys for Friedreich Ataxia
Source: https://unsplash.com/photos/ZHys6xN7sUE

Now Approved: Skyclarys for Friedreich Ataxia

  Until recently, the only therapeutic options for people with Friedreich ataxia were symptomatic and focused on symptom management: mobility aids, surgery, psychotherapy, speech therapy, heart medications, hearing and vision…

Continue Reading Now Approved: Skyclarys for Friedreich Ataxia
Potential Treatment for Friedreich’s Ataxia Earns Orphan Drug and Rare Pediatric Disease Designations
source: pixabay.com

Potential Treatment for Friedreich’s Ataxia Earns Orphan Drug and Rare Pediatric Disease Designations

According to a story from GlobeNewswire, the gene therapy company LEXEO Therapeutics has recently announced that its investigational gene therapy LX2006 has been granted both Orphan Drug designation and Rare…

Continue Reading Potential Treatment for Friedreich’s Ataxia Earns Orphan Drug and Rare Pediatric Disease Designations
Can Endurance Training Prevent Friedreich’s Ataxia Onset? One Study Suggests Yes
https://pixabay.com/en/exercise-jogging-man-person-1835032/

Can Endurance Training Prevent Friedreich’s Ataxia Onset? One Study Suggests Yes

Exercising has many physical and emotional benefits. It can manage blood sugar levels, improve your mood, assist with weight loss, or even strengthen your memory. Endurance training, specifically, benefits tissue…

Continue Reading Can Endurance Training Prevent Friedreich’s Ataxia Onset? One Study Suggests Yes

Very First Patient Dosed with Investigational Therapy for Friedreich’s Ataxia in Phase 2 Clinical Trial

Friedreich's Ataxia Friedreich's ataxia (FRDA) is a rare disease which is caused by a frataxin deficiency. This deficiency results in the degeneration of nerves within the spinal cord. This nerve…

Continue Reading Very First Patient Dosed with Investigational Therapy for Friedreich’s Ataxia in Phase 2 Clinical Trial